𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bcl-2 antisense therapy in B-cell malignant proliferative disorders

✍ Scribed by Asher Chanan-Khan; Myron S. Czuczman

Book ID
107531855
Publisher
Springer
Year
2004
Tongue
English
Weight
285 KB
Volume
5
Category
Article
ISSN
1527-2729

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Do bcl-2 and survivin help distinguish b
Do bcl-2 and survivin help distinguish benign from malignant B-cell lymphoid aggregates in bone marrow biopsies?
✍ Amish M. Gandhi; Jonathan M. Ben-Ezra πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 254 KB

## Abstract __Bcl__‐2 and survivin are cellular proteins that are known to be inhibitors of apoptosis and are commonly found in malignant tissues, including lymphomas. In previous studies, it has been shown that staining for __bcl__‐2 can help distinguish between benign and malignant lymphoid aggre

BCL-2 oncoprotein (p26) in splenic lymph
BCL-2 oncoprotein (p26) in splenic lymphoma with villous lymphocytes: A comparative study with other chronic B-cell disorders
✍ Lima, Margarida; Teixeira, Maria dos Anjos; QueirΓ³s, Maria LuΓ­s; Ribeiro dos San πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 49 KB πŸ‘ 1 views

We compared the expression of the BCL-2 oncoprotein (p26) on B cells from 24 patients with splenic lymphoma with circulating villous lymphocytes (SLVL) with that observed on normal, mature B lymphocytes and on neoplastic B cells from 91 patients with other chronic B-cell malignancies. SLVL B cells s